Conversion to Aflibercept for Diabetic Macular Edema Unresponsive To Bevacizumab in Chicago Cook County Health System

被引：0
|
作者：
Cunningham, Christy [1 ]
Sahni, Sakshi [2 ]
Farahani, Mina [1 ]
Thomas, Catherine [2 ]
Anderson-Nelson, Susan [1 ]
Raiji, Veena [1 ,3 ]
Skondra, Dimitra [1 ,4 ]
机构：
[1] J Stroger Cook Cty Hosp, Chicago, IL USA
[2] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA
[3] Loyola Univ, Ophthalmol, Maywood, IL 60153 USA
[4] Northwestern, Feinberg Sch Med, Chicago, IL USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
2077
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [21] Intravitreal Aflibercept for Diabetic Macular Edema
    Korobelnik, Jean-Francois
    Do, Diana V.
    Schmidt-Erfurth, Ursula
    Boyer, David S.
    Holz, Frank G.
    Heier, Jeffrey S.
    Midena, Edoardo
    Kaiser, Peter K.
    Terasaki, Hiroko
    Marcus, Dennis M.
    Nguyen, Quan D.
    Jaffe, Glenn J.
    Slakter, Jason S.
    Simader, Christian
    Soo, Yuhwen
    Schmelter, Thomas
    Yancopoulos, George D.
    Stahl, Neil
    Vitti, Robert
    Berliner, Alyson J.
    Zeitz, Oliver
    Metzig, Carola
    Brown, David M.
    OPHTHALMOLOGY, 2014, 121 (11) : 2247 - 2254
  • [22] Aflibercept for the treatment of diabetic macular edema
    Harkins, Keegan A.
    Haschke, Mary
    Do, Diana V.
    IMMUNOTHERAPY, 2016, 8 (05) : 503 - 510
  • [23] Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
    Mira, Filipe
    Paulo, Manuel
    Henriques, Filipe
    Figueira, Joao
    JOURNAL OF OPHTHALMOLOGY, 2017, 2017
  • [24] Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
    Bobak Bahrami
    Thomas Hong
    Andrew Chang
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 1453 - 1454
  • [25] Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab
    Ebrahimiadib, Nazanin
    Lashay, Alireza
    Riazi-Esfahani, Hamid
    Jamali, Sepideh
    Khodabandeh, Alireza
    Zarei, Mohammad
    Roohipoor, Ramak
    Khojasteh, Hassan
    Bazvand, Fatemeh
    Ojani, Mina
    Shahabinejad, Mojtaba
    Yaseri, Mehdi
    Modjtahedi, Bobeck S.
    Davoudi, Samaneh
    Riazi-Esfahani, Mohammad
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2020, 51 (03): : 145 - 151
  • [26] One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
    Salimi, Ali
    Vila, Natalia
    Modabber, Milad
    Kapusta, Michael
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (02) : 360 - +
  • [27] Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
    Bahrami, Bobak
    Hong, Thomas
    Chang, Andrew
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (07) : 1453 - 1454
  • [28] Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
    Pessoa, Bernardete
    Malheiro, Luisa
    Carneiro, Ines
    Monteiro, Silvia
    Coelho, Joao
    Coelho, Constanca
    Figueira, Joao
    Meireles, Angelina
    Melo Beirao, Joao Nuno
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 253 - 260
  • [29] Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
    Alsaedi, Nasser G.
    Alselaimy, Ruba M.
    Alshamrani, Abdulaziz A.
    AlAjmi, Muhammed
    Khandekar, Rajiv
    Al-Dhibi, Hassan
    Al-Abdullah, Abdulelah A.
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 2975 - 2980
  • [30] Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema
    Hutton, David W. W.
    Glassman, Adam R. R.
    Liu, Danni
    Sun, Jennifer K. K.
    JAMA OPHTHALMOLOGY, 2023, 141 (03) : 268 - 274
12345